Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE SODIUM PHOSPHATE versus EOHILIA.
BETAMETHASONE SODIUM PHOSPHATE vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to suppress inflammation, immune response, and reduce capillary permeability.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
0.5-9 mg/day IV or IM in divided doses every 12-24 hours; acute conditions may require 4-8 mg IV initially.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours (plasma); biological half-life (HPA axis suppression): 24-36 hours.
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Renal: 90-95% as inactive metabolites; biliary/fecal: <5%.
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category D/X
Category C
Corticosteroid
Corticosteroid